These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 19125911)

  • 21. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic lupus erythematosus induced by interferon β1 therapy in a patient with multiple sclerosis.
    Bahri DM; Khiari H; Essouri A; Laadhar L; Zaraa I; Mrabet A; Meddeb N; Sellami S
    Fundam Clin Pharmacol; 2012 Apr; 26(2):210-1. PubMed ID: 21323997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a.
    Pohl D; Rostasy K; Gärtner J; Hanefeld F
    Neurology; 2005 Mar; 64(5):888-90. PubMed ID: 15753430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
    Walther EU; Dietrich E; Hohlfeld R
    Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis.
    Bonaci-Nikolic B; Jeremic I; Andrejevic S; Sefik-Bukilica M; Stojsavljevic N; Drulovic J
    Lupus; 2009 Jan; 18(1):78-80. PubMed ID: 19074173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early use of interferon beta patients with multiple sclerosis.
    Bosley EB; Capildeo R
    Int J Clin Pract Suppl; 2002 Sep; (131):17-22. PubMed ID: 12564808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythema elevatum et diutinum, multiple sclerosis and interferon beta.
    Gil M; Chizzolini C; Kaya G; Hauser C
    Dermatology; 2004; 209(1):75-6. PubMed ID: 15237277
    [No Abstract]   [Full Text] [Related]  

  • 28. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis.
    Alanoglu G; Kilbas S; Arslan C; Senol A; Kutluhan S
    Mult Scler; 2007 Jun; 13(5):683-5. PubMed ID: 17548453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon causes no myasthenia in a seropositive patient with multiple sclerosis.
    Shimizu H; Kataoka H; Kawahara M; Hirano M; Furiya Y; Ueno S
    Clin Neurol Neurosurg; 2007 Apr; 109(3):277-8. PubMed ID: 17118531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
    Feinstein A; O'Connor P; Feinstein K
    J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [High doses of interferon in the treatment of multiple sclerosis].
    Muñoz D
    Rev Neurol; 2001 May 1-15; 32(9):899. PubMed ID: 11424041
    [No Abstract]   [Full Text] [Related]  

  • 33. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.
    Rieckmann P; O'Connor P; Francis GS; Wetherill G; Alteri E
    Drug Saf; 2004; 27(10):745-56. PubMed ID: 15350158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient satisfaction with an injection device for multiple sclerosis treatment.
    Cramer JA; Cuffel BJ; Divan V; Al-Sabbagh A; Glassman M
    Acta Neurol Scand; 2006 Mar; 113(3):156-62. PubMed ID: 16441244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients' views of interferon therapy in MS.
    Burgess M
    Prof Nurse; 1998 Jun; 13(9):588-92. PubMed ID: 9782975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
    Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis.
    Di Rezze S; Gupta S; Durastanti V; Millefiorini E; Pozzilli C; Bagnato F
    Mult Scler; 2007 Apr; 13(3):343-7. PubMed ID: 17439903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-beta-1a treatment in multiple sclerosis patients.
    Mirowska D; Skierski J; Paź A; Koronkiewicz M; Zaborski J; Kruszewska J; Członkowski A; Członkowska A
    J Neurol; 2003 Oct; 250(10):1229-36. PubMed ID: 14586608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
    [No Abstract]   [Full Text] [Related]  

  • 40. An open labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.
    Ozuma J
    J Neurosci Nurs; 1996 Apr; 28(2):72. PubMed ID: 8718753
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.